
The candidate vaccine’s next steps will be going through the FDA’s Biologics License Application process.
Tinidazole (Tindamax) is the first new drug for the treatment of bacterial vaginosis in 10 years and will provide a shorter course of treatment with fewer daily doses than the current standard of treatment, according to its manufacturer Mission Pharmacal.






